Search

760 Result(s)
Sort by

CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Making sustainable medicines through eco-design

Making sustainable medicines through eco-design

Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Aftopor®/Aftovaxpur®/Aftovax®

Aftopor®/Aftovaxpur®/Aftovax®

FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
equine asthma

equine asthma

Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
GPP: there is more than you see

GPP: there is more than you see

Generalized Pustular Psoriasis is a rare neutrophilic skin condition. Watch an animation to learn about its recurrent nature and how it affects people
Cooperation with The Defeat-NCD Partnership

Cooperation with The Defeat-NCD Partnership

Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Collaborating for social impact

Collaborating for social impact

Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Lady, a guide dog in the office

Lady, a guide dog in the office

A great partnership between a Boehringer Ingelheim employee and her guide dog at work. Their relationship goes beyond the human-animal bond.